Cell line · CVCL_1547
NCI-H23
Cancer cell line, Homo sapiens. Lung adenocarcinoma. 128 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. NCI-H23. Cell lines, record CVCL_1547. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1547
On this page
Cell line
As Cellosaurus gives it.
- Name
- NCI-H23
- Accession
- CVCL_1547
- RRID
- RRID:CVCL_1547
- Synonyms
- NCI.H23, NCI H23, H-23, H23, NCIH23
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 51Y
- Category
- Cancer cell line
- Diseases
- Lung adenocarcinoma (NCIt C3512)
- Derived from
- Lung (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2026-06-25
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers128
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| E3 ubiquitin ligase MAGI3‑mediated TAZ ubiquitination suppresses the non‑small cell lung cancer occurrence and development by targeting the Wnt pathway. | Int J Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. | Oncogene | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HES1 inhibition overcomes CDK4/6 inhibitor resistance by targeting cancer stemness in lung adenocarcinoma. | J Exp Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Virtual Tumors Enable Prediction of Personalized Therapeutic Combinations for Non-Small Cell Lung Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting KRAS Codon 13 Mutations Using Direct Combination Approaches in Non-Small Cell Lung Cancer. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MPND Loss Epigenetically Activates TGFβ/SMAD3 Signaling to Drive Tumor Progression and Metastasis in Non-Small Cell Lung Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Functional genomic analysis reveals HAVCR1 as the key regulator of 5q33.3 locus linked to hyperlipidemia. | HGG Adv | 2026 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 128
See all 128 papersRelatives4
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | HCC60 | CVCL_G002 | Has a recorded problem | Cell lines |
| Derived from it | HyCyte NCI-H23-Luc | CVCL_E3I7 | Cell lines | |
| Derived from it | NCI-H23-Luc | CVCL_4W97 | Cell lines | |
| Derived from it | NCI-H23/GEM-R | CVCL_ZZ80 | Cell lines |
Cell banks6
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRL-5800 | ATCC | |
| AddexBio | C0016005/4861 | Cellosaurus | |
| CLS | 305044 | CLS | |
| Hysigen | TCH-C280 | Hysigen | |
| KCLB | 90023 | KCLB | |
| NCI-DCTD | NCI-H23 | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1547
GET https://conductscience.org/api/cell-lines/v1/CVCL_1547/papers?page=2